NCT05576480 2025-08-28
SPARC
Ruijin Hospital
Phase 2 Recruiting
Clinical Trials
7 trialsNCT05229003 2024-07-03
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
Fudan University
Phase 2 Recruiting
NCT06341530 2024-04-02
Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Recruiting
NCT05494060 2023-11-07
EXPLORING
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT06114225 2023-11-02
PROMIS
Ruijin Hospital
Phase 2 Recruiting
NCT06081673 2023-10-13
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2 Recruiting
NCT06051851 2023-09-25
RCT-PAAG
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2 Recruiting